Illumina, Inc. (ILMN)

221,61 +1,84 (+0,84%) Börsenschluss: 04:00PM EDT

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
United States
858 202 4500
https://www.illumina.com

Sektor(en): Healthcare
Branche: Diagnostics & Research
Vollzeitmitarbeiter: 11.500

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Francis A. deSouza	CEO & Director	N/A	N/A	1971
Dr. Alexander Aravanis M.D., Ph.D.	CTO & Head of Research and Product Devel.	1,05M	N/A	1977
Mr. Charles E. Dadswell	Sr. VP, Gen. Counsel & Sec.	N/A	N/A	1959
Ms. Susan H. Tousi	Chief Commercial Officer	1,04M	N/A	1969
Stephanie Campos	Pres	N/A	N/A	N/A
Dr. Joydeep Goswami M.B.A., Ph.D.	CFO, Chief Strategy & Corp. Devel. Officer	N/A	N/A	1971
Mr. Kevin Carl Pegels	Chief of Global Operations	N/A	N/A	N/A
Mr. Scott Ericksen	VP & Chief Accounting Officer	N/A	N/A	1972
Ms. Carissa Rollins	Chief Information Officer	N/A	N/A	N/A
Ms. Sallilyn Schwartz	VP of Investor Relations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Further, it provides whole-genome sequencing, genotyping, NIPT, and product support services; and Galleri, a multi-cancer early detection test. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Further, it markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Corporate Governance

Illumina, Inc.s ISS Governance QualityScore, Stand 1. März 2023, lautet 3. Die grundlegenden Scores sind Audit: 1, Vorstand: 3, Shareholderrechte: 7, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.